Treatment-experienced patients with RAMs — resistance-associated mutations — remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patient’s ART history. How will new and in-development agents affect the equation?
Which drug combinations are right? Where does the balance between side effects and adherence lie?
These are some of the questions Dr. Brian Wood from the Division of Allergy and Infectious Diseases at the University of Washington in Seattle addresses in this eHIV Review podcast.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
","author_name":"eHIV Review"}